ALIMERA SCIENCES INC (ALIM)
US0162592028 - Common Stock
ALIM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ALIM have multiple concerns. ALIM is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year ALIM has reported negative net income.
ALIM had a negative operating cash flow in the past year.
In the past 5 years ALIM always reported negative net income.
In the past 5 years ALIM always reported negative operating cash flow.
1.2 Ratios
ALIM has a Return On Assets of -10.16%. This is in the better half of the industry: ALIM outperforms 72.82% of its industry peers.
ALIM's Return On Equity of -39.38% is fine compared to the rest of the industry. ALIM outperforms 62.05% of its industry peers.
ALIM's Return On Invested Capital of 0.12% is fine compared to the rest of the industry. ALIM outperforms 76.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.16% | ||
| ROE | -39.38% | ||
| ROIC | 0.12% |
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALIM's Operating Margin of 0.20% is fine compared to the rest of the industry. ALIM outperforms 76.92% of its industry peers.
ALIM has a Gross Margin of 86.39%. This is amongst the best in the industry. ALIM outperforms 90.26% of its industry peers.
ALIM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.2% | ||
| PM (TTM) | N/A | ||
| GM | 86.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALIM is destroying value.
The number of shares outstanding for ALIM has been increased compared to 1 year ago.
Compared to 5 years ago, ALIM has more shares outstanding
ALIM has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.37, we must say that ALIM is in the distress zone and has some risk of bankruptcy.
ALIM has a Altman-Z score (-1.37) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.80 is on the high side and indicates that ALIM has dependencies on debt financing.
ALIM's Debt to Equity ratio of 1.80 is on the low side compared to the rest of the industry. ALIM is outperformed by 78.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.8 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.37 |
ROIC/WACC0.01
WACC9.95%
2.3 Liquidity
A Current Ratio of 2.79 indicates that ALIM has no problem at all paying its short term obligations.
The Current ratio of ALIM (2.79) is comparable to the rest of the industry.
A Quick Ratio of 2.62 indicates that ALIM has no problem at all paying its short term obligations.
ALIM's Quick ratio of 2.62 is in line compared to the rest of the industry. ALIM outperforms 49.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 90.66% over the past year.
The Revenue has grown by 69.76% in the past year. This is a very strong growth!
ALIM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.62% yearly.
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%
3.2 Future
The Earnings Per Share is expected to grow by 22.30% on average over the next years. This is a very strong growth
ALIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.81% yearly.
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ALIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 28.59 indicates a quite expensive valuation of ALIM.
Based on the Price/Forward Earnings ratio, ALIM is valued a bit cheaper than 77.44% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ALIM to the average of the S&P500 Index (23.53), we can say ALIM is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 28.59 |
4.2 Price Multiples
77.95% of the companies in the same industry are more expensive than ALIM, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 28.66 |
4.3 Compensation for Growth
ALIM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALIM's earnings are expected to grow with 30.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.56%
EPS Next 3Y30.12%
5. Dividend
5.1 Amount
ALIM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALIMERA SCIENCES INC
NASDAQ:ALIM (9/13/2024, 8:00:00 PM)
After market: 5.54 0 (0%)5.54
-0.01 (-0.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.2%
Inst Owner Change0%
Ins Owners30.17%
Ins Owner Change-5.28%
Market Cap301.27M
Analysts48.89
Price Target5.78 (4.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.01%
Min EPS beat(2)-107.6%
Max EPS beat(2)-60.41%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.13%
Min Revenue beat(2)1.39%
Max Revenue beat(2)2.87%
Revenue beat(4)4
Avg Revenue beat(4)2.76%
Min Revenue beat(4)0.83%
Max Revenue beat(4)5.96%
Revenue beat(8)5
Avg Revenue beat(8)-1.87%
Revenue beat(12)7
Avg Revenue beat(12)-1.43%
Revenue beat(16)10
Avg Revenue beat(16)1.21%
PT rev (1m)0%
PT rev (3m)-29.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 28.59 | ||
| P/S | 3.02 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.77 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.66 |
EPS(TTM)-0.31
EYN/A
EPS(NY)0.19
Fwd EY3.5%
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS1.83
BVpS0.71
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.16% | ||
| ROE | -39.38% | ||
| ROCE | 0.15% | ||
| ROIC | 0.12% | ||
| ROICexc | 0.13% | ||
| ROICexgc | 0.56% | ||
| OM | 0.2% | ||
| PM (TTM) | N/A | ||
| GM | 86.39% | ||
| FCFM | N/A |
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
F-Score4
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.8 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.55 | ||
| Cap/Depr | 1.81% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 0.03 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | -1.37 |
F-Score4
WACC9.95%
ROIC/WACC0.01
Cap/Depr(3y)299.05%
Cap/Depr(5y)185.34%
Cap/Sales(3y)31.69%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%
EBIT growth 1Y101.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3584.36%
EBIT Next 3Y329.62%
EBIT Next 5Y187.7%
FCF growth 1Y62.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3YN/A
OCF growth 5YN/A